0TDF.IL,0P0001JE14,1031 (0TDF.IL)

38.24

-1.11

(-2.82%)

As of July 23 at 9:00:00 PM GMT+1. Market Open.

Trump is hailing $2 trillion in new company investments. Most of it comes from Big Tech.

President Trump has touted $2 trillion in new company investments since Inauguration Day. The lion's share comes from Big Tech, according to a Yahoo Finance analysis.

Yahoo Finance yesterday

ORCL

RHHBF

RHHBY
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide1The test delivers results in just 18 minutes on Roche’s cobas analysers, providing a fast and reliable diagnostic method.The test enables earlier identification of patients with significant liver fibrosis, potentially improving outcomes through timely management and access to emerging therapies. Basel, 0

GlobeNewswire 6 days ago

RHHBF

RHHBY

RHHVF
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Eli Lilly CEO says Trump tariff threat has already achieved the goal of repatriating manufacturing in pharma.

Yahoo Finance 10 days ago

PFE

JNJ

RHHBF
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example at home1-4 Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings3Phesgo has the potential to reduce treatment administration costs by up to 80% in Western Europe, and 85% of patients prefer SC over IV administ

GlobeNewswire 12 days ago

RHHBF

RHHBY

RHHVF
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer

The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level of diagnostic precision not possible with traditional manual scoring methods. This Breakthrough Device Designation (BDD) demonstrates Roche’s continued innovation in companion diagnostics and digital pathology to enable more precise diagnosis in oncology. Basel, 29 Apri

GlobeNewswire 13 days ago

RHHBF

RHHBY

RHHVF
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

SOUTH SAN FRANCISCO, Calif., April 25, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil). The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%. For the key secondary endpo

Business Wire 17 days ago

RHHBF

RHHBY

RHHVF
Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push

Roche posted higher-than-expected first-quarter sales, driven by robust demand for its key drugs, as the company takes active steps to preempt looming U.S. import tariffs.

The Wall Street Journal 18 days ago

RHHBF

RHHBY

RHHVF
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

Group sales grew by 6%1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions.Pharmaceuticals Division sales rose by 8% (9% in CHF) on continued strong demand for a broad range of our medicines; top growth drivers were Phesgo (breast cancer), Vabysmo (severe eye diseases), Xolair (allergies) and Hemlibra (haemophilia A).Diagnostics Division sales remained stable with high demand across products and regions offsetting the impact of the rec

GlobeNewswire 18 days ago

RHHBF

RHHBY

RHHVF
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)

Roche, in collaboration with Universitätsklinikum Heidelberg, has developed a Chest Pain Triage algorithm – a CE-marked IVD medical device1 set to transform cardiac careThis novel algorithm offers a standardised assessment, helping emergency room doctors to make confident clinical decisions in ruling in or ruling out heart attacks (acute myocardial infarction)Cardiovascular disease causes a third of worldwide deaths2, with chest pain being the second highest reason for emergency department (ED)

GlobeNewswire 19 days ago

RHHBF

RHHBY

RHHVF
Drug Companies Step Up 'Make in America' Plans to Counter Tariffs

Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs loom over medicines made abroad. Regeneron, which makes drugs for skin and respiratory diseases, is doubling its U.S. manufacturing capacity in a new $3 billion, 10-year agreement with Fujifilm Diosynth Biotechnologies. Fujifilm’s plant in Holly Springs, N.C., will make bulk drug material for Regeneron medicines.

The Wall Street Journal 19 days ago

REGN

RHHBF

RHHBY
Trending tickers: Nvidia, Tesla, Roche, Novo Nordisk and Fresnillo

The latest investor updates on stocks that are trending on Tuesday.

Yahoo Finance UK 20 days ago

^GSPC

^FTSE

^IXIC
Roche, Apple, TSMC: Tracking Corporate Spending Pledges Under Trump

Swiss drugmaker Roche unveiled a $50 billion plan to invest in the U.S., adding to a series of commitments by big corporations. 🚢 CMA CGM: The French shipping company aims to invest $20 billion in the U.S., creating 10,000 jobs. CMA CGM will triple its U.S.-flagged fleet, upgrade port facilities and create a Chicago airfreight hub. 💉 Eli Lilly: The drugmaker behind Zepbound and Mounjaro plans to invest $27 billion building four manufacturing plants in the U.S. Lilly expects the project will employ 10,000 construction workers.

The Wall Street Journal 20 days ago

RHHBF

RHHBY

RHHVF
Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom

The pharma giant said the investment would create more than 12,000 jobs, as it joins rival Novartis in expanding its footprint in the country amid President Trump’s tariff threats.

The Wall Street Journal 20 days ago

RHHBF

RHHBY

RHHVF
Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years

USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California and an additional site location to be announced soonInvestments will create more than 12,000 new jobs: 1,000 at Roche and more than 11,000 in support of new US manufacturing capabilities Roche already has a significant existing US presence with more than 25,000 employees, 15 R&D centres and 13 manufacturing

GlobeNewswire 20 days ago

RHHBF

RHHBY

RHHVF
Stocks to watch this week: Tesla, Alphabet, Intel, Boeing and Unilever

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 24 days ago

DELHY

DLVHF

IHCPF
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed for people who relapse or have refractory diseaseThis Columvi regimen offers a much needed off-the-shelf and fixed-duration treatment option for those ineligible for transplant Basel, 14 April 2025 - Roche

GlobeNewswire 28 days ago

RHHBF

RHHBY

RHHVF
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

The latest investor updates on stocks that are trending on Wednesday.

Yahoo Finance UK last month

DAL

GM

SVNDF
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

SOUTH SAN FRANCISCO, Calif., April 03, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. Highlights included presentations from the ongoing trontinemab Phase Ib/IIa Brainshuttle™ AD study demonstrating dose-dependent rapid amyloid depletion from the brain and the potential of the Elecsys® pTau181 plasma test to rule out amylo

Business Wire last month

RHHBF

RHHBY

RHHVF
Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study Data on the Elecsys® pTau181 plasma test demonstrate potential to accurately rule out amyloid pathology, one of the hallmarks of Alzheimer’s diseaseRoche will initiate a Phase III programme for trontinemab later this year based on totality of data Basel, 3 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data were presented at the AD/

GlobeNewswire last month

RHHBF

RHHBY

RHHVF
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif., April 02, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intravenous (IV) infusion to the currently approved Ocrevus IV 600 mg dose in people with relapsing multiple sclerosis (RMS) did not meet its primary endpoint in showing additional benefit in slowing disability progression, as measured by a composite disability endpoint over a period of a

Business Wire last month

RHHBF

RHHBY

RHHVF

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TARIFFS LATEST

0TDF.IL,0P0001JE14,1031 (0TDF.IL)

Trump is hailing $2 trillion in new company investments. Most of it comes from Big Tech.

Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer

New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs

Trending tickers: Nvidia, Tesla, Roche, Novo Nordisk and Fresnillo

Roche, Apple, TSMC: Tracking Corporate Spending Pledges Under Trump

Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom

Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years

Stocks to watch this week: Tesla, Alphabet, Intel, Boeing and Unilever

European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy

Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis